Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DCFS | ISIN: US92673K1088 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
1,825 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIGIL NEUROSCIENCE INC Chart 1 Jahr
5-Tage-Chart
VIGIL NEUROSCIENCE INC 5-Tage-Chart

Aktuelle News zur VIGIL NEUROSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.04.Vigil Neuroscience bringt Alzheimer-Medikament in Phase-2-Studien2
VIGIL NEUROSCIENCE Aktie jetzt für 0€ handeln
02.04.Vigil Neuroscience advances Alzheimer's drug into Phase 2 trials2
13.03.Vigil Neuroscience GAAP EPS of -$0.573
13.03.Vigil Neuroscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
13.03.Vigil Neuroscience, Inc. - 10-K, Annual Report1
13.03.Vigil Neuroscience, Inc. - 8-K, Current Report-
13.03.Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates450- Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 - - On track to report...
► Artikel lesen
02.03.Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 20253
23.01.Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q33
23.01.Vigil Neuroscience Reports Positive Phase 1 Data Supporting Continued Development Of VG-39271
23.01.Vigil Neuroscience gains as Alzheimer's drug reaches mid-stage trial1
23.01.Vigil Neuroscience-Aktien steigen nach positiven Daten aus Alzheimer-Studie2
23.01.Vigil Neuroscience schreitet mit Alzheimer-Medikament zu Phase-2-Studie voran2
23.01.Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial2
23.01.Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease117- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer's disease (AD) - - Robust and dose-dependent...
► Artikel lesen
23.01.Vigil Neuroscience, Inc. - 8-K, Current Report-
08.01.Vigil Neuroscience, Inc.: Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones152- On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 - - Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart...
► Artikel lesen
07.11.24Vigil Neuroscience, Inc. - 10-Q, Quarterly Report-
07.11.24Vigil Neuroscience, Inc. - 8-K, Current Report-
17.09.24Vigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927214WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1